PARP inhibitor exerts an anti-tumor effect via LMO2 and synergizes with cisplatin in natural killer/T cell lymphoma

PARP inhibitor exerts an anti-tumor effect via LMO2 and synergizes with cisplatin in natural killer/T cell lymphoma

Abstract Background PARP inhibitor (PARPi), as a kind of DNA damage repair inhibitor, has been shown to be effective in various solid tumors and hematologic malignancies. Natural killer/T cell lymphoma (NKTCL) is a highly aggressive malignancy, the treatment of which has long been a major challenge...

Full description

Bibliographic Details
Main Authors: Jiazhuo Wu, Cunzhen Shi, Hongwen Li, Wenting Song, Shuo Huang, Jianxiang Zhang, Wencai Li, Zhaoming Li, Mingzhi Zhang
Format: Article
Language:English
Published: BMC 2023-07-01
Series:BMC Medicine
Subjects:
PARP inhibitor
LMO2
Natural killer/T cell lymphoma
DNA damage repair
Online Access:https://doi.org/10.1186/s12916-023-02904-9

Similar Items

Similar Items